Biohaven Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BHVN New York 2830 www.biohaven.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biohaven Ltd.

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy - Jan 13th, 2025 4:15 pm
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - Jan 13th, 2025 1:04 am
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 10:54 pm
Insider Buying: Biohaven Independent Director Bought US$1.0m Of Shares - Jan 3rd, 2025 10:04 am
Company News for Jan 2, 2025 - Jan 2nd, 2025 8:39 am
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - Dec 17th, 2024 7:23 pm
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Dec 17th, 2024 11:06 am
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - Dec 16th, 2024 12:30 pm
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting - Dec 6th, 2024 12:30 pm
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study - Nov 25th, 2024 4:51 pm
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - Nov 25th, 2024 12:30 pm
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - Nov 12th, 2024 9:05 pm
Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy - Oct 7th, 2024 8:13 pm
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock - Oct 3rd, 2024 12:22 pm
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Oct 2nd, 2024 8:05 pm
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - Oct 1st, 2024 10:00 am
Biohaven Announces Proposed Public Offering of Common Shares - Sep 30th, 2024 8:05 pm
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - Sep 30th, 2024 11:30 am
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More - Sep 26th, 2024 4:06 pm
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Sep 24th, 2024 2:53 pm